FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older

by NASDAQ Market News August 10, 2020

NASDAQ Market News
Click here to email author

Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA’s CHMP

Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis

Ads